CD8B and cancer: Both T cell markers (PD-1, CD8A, and CD8B) and immune checkpoint blockade PD-L1 show increased expression in samples with SCMs compared to samples without SCMs (Figure 7), indicating alternative splice forms induced by SCMs increase the overall immunogenicity of these cancers.